John Kang, The Asian Lawyer

January 03, 2019 |

Zein El Hassan joins KPMG Law as a partner from Norton Rose Fulbright, where he led the firm's Australia financial services risk advisory team.

By John Kang

2 minute read

December 20, 2018 |

The U.K.-based firm, which has been expanding in other regions of the world, is now focused on huge growth in the Asia Pacific.

By John Kang

6 minute read

December 17, 2018 |

The deal will be the Japanese company's largest-ever acquisition and make the Tokyo-based conglomerate the world's second-largest heavy electrical equipment maker by revenue.

By John Kang

2 minute read

December 17, 2018 |

Create+65 is the Magic Circle firm's first innovation lab globally and is part of the firm's Singapore-based innovation hub for the Asia-Pacific region launched earlier this year.

By John Kang

2 minute read

December 17, 2018 |

In total, a team of 42 lawyers and support staff is joining the Australian firm.

By John Kang

3 minute read

December 14, 2018 |

Construction partner Fabio Fior and financial services partner Natalie Cambrell join the firm from Squire Patton Boggs and Australian firm Lander & Rogers, respectively.

By John Kang

2 minute read

December 13, 2018 |

David Lyons is the latest in a string of partner exits from the Anglo-Australian firm.

By John Kang

2 minute read

December 13, 2018 |

Chatchai Inthasuwan, who will lead the disputes practice in Bangkok, is the third global firm partner to be hired by the Japanese firm's Thailand arm in the past 12 months.

By John Kang

2 minute read

December 12, 2018 |

Eversheds Sutherland and Reynolds Porter Chamberlain are the latest international firms to relocate their Hong Kong offices from Central to Quarry Bay, where rents are much lower than in Central—the most expensive office location in the world.

By John Kang

3 minute read

December 12, 2018 |

Shearman, Allen & Overy advised on a $1.7 billion energy project in Indonesia, Mayer Brown on a $1.2 billion Japanese mining deal, and Wilson Sonsini, Shearman on a $1.1 billion Chinese biotech listing in Hong Kong.

By John Kang

4 minute read